Skip to main content
Clinical Trials/NCT01684176
NCT01684176
Completed
Not Applicable

Pharmacist Intervention Programme to Improve Medication Adherence in Stroke Patients

Odense University Hospital1 site in 1 country211 target enrollmentAugust 2012

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Stroke
Sponsor
Odense University Hospital
Enrollment
211
Locations
1
Primary Endpoint
Medication Adherence to antiplatelets, anticoagulants and statins measured by proportion of days covered (PDC).
Status
Completed
Last Updated
11 years ago

Overview

Brief Summary

Patient suffering a Transient Ischemic Attack (TIA) or stroke are subsequently at high risk of a new stroke, however, poor adherence to secondary prevention medications occurs frequently within this patient group. The purpose of this study is to evaluate whether a complex tailored pharmacist intervention will lead to increased adherence to secondary stroke prevention medications and less new stroke events when compared to a usual care group. Interventions focus on motivational interviewing, medication review and telephone follow up.

Registry
clinicaltrials.gov
Start Date
August 2012
End Date
June 2014
Last Updated
11 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Ulla Hedegaard

PhD student, MSc (pharm)

Odense University Hospital

Eligibility Criteria

Inclusion Criteria

  • Age: 18 years or older
  • Patient admitted or receiving ambulatory treatment for an acute transient ischemic attack or ischemic stroke which has occurred within the previous 30 days.
  • The patient or a carer usually dispenses the patient's medications
  • Written consent

Exclusion Criteria

  • Cognitive or physical impairment that would preclude comprehension of a conversation
  • Terminal illness
  • Lives in a care home or an institution
  • Receives dose dispensed medicine from a pharmacy
  • Medicine is dispensed by a nurse in the patient's home
  • Correctional mental health patients

Outcomes

Primary Outcomes

Medication Adherence to antiplatelets, anticoagulants and statins measured by proportion of days covered (PDC).

Time Frame: One year from inclusion

For antiplatelets, anticoagulants and statins: Percent of patients that are at least 80% adherent (PDC>0.8)

Time Frame: 1 year from inclusion

Secondary Outcomes

  • Non-persistence with thromboprophylactic agents ( antiplatelets, anticoagulants, statins and antihypertensives) measured by percent of patients that are not supplied with medication for more than 3 continuous months(One year from inclusion)
  • Accept rate for thromboprophylactic agents measured by percent of patients starting treatment within 0-90 days after discharge.(3 months from discharge)
  • Composite endpoint: stroke, myocardial infarction or cardiovascular death(One year from inclusion)
  • Medication Adherence to antihypertensives measured by proportion of days covered (PDC)(One year from inclusion)
  • Percent of patients that are at least 80% adherent (PDC>0.8) to antihypertensives(One year from inclusion)

Study Sites (1)

Loading locations...

Similar Trials